Abstract Body

Background: Perinatal guidelines include ritonavir-boosted darunavir (DRV/r) as an alternative protease inhibitor for use in antiretroviral (ARV)-naïve pregnant women. The dosing recommendation for ARV-naive patients is DRV/r 800/100mg QD but pharmacokinetic data on this dose in pregnant women are limited. Methodology: Patients treated with DRV/r (800/100mg QD) during pregnancy had intensive steady-state 24-hour PK profiles in the 3rd trimester and at least 2 weeks postpartum. Geometric mean ratios (GMR) and 90% confidence intervals (CI) were calculated for PK parameters 3rd trimester/postpartum. Unbound concentrations were determined using an ultracentrifugation method. Results: 15 patients were included in the analysis, 11 were treatment experienced at conception. 7 patients were Black and 8 Caucasian. Seven paired PK curves (3rd trimester and postpartum) were available. Median gestational age at delivery was 38 (36-41) weeks. Approaching delivery 73% had an HIV viral load <50 cps/mL, 93% <1000 cps/mL. Two weeks prior to delivery one patient still had a significant viraemia: (28,711 copies/mL). This patient was thought to be non-adherent and had directly observed therapy until delivery. All children were born uninfected. No congenital abnormalities were reported.GMR (90% CI) of DRV PK parameters 3rd trimester/ postpartum were: 0.63 (0.51-0.77) for AUC; 0.72 (0.57-0.93) for Cmax; 0.36 (0.22-0.58) for C24h. Mean free fraction (95%CI) was 12% (11-14%) in the 3rd trimester and 10% (7-13%) postpartum. 2/15 of the patients showed DRV concentrations <0.55 mg/L (EC50 for resistant virus) in the 3rd trimester, versus none postpartum. The median (min-max) cord blood/maternal ratios (n=6) were 0.12 (0.08-0.35). Conclusions: Third trimester darunavir exposure when administered as 800/100mg QD was significantly lower than postpartum. Trough concentrations were approaching the Ctrough target minimum, indicating that this dose is likely to lead to sub-therapeutic concentrations during pregnancy, especially for treatment experienced patients. This decrease seems not to be compensated by a higher free fraction during pregnancy. DRV/r 600/100mg BID is suggested to be the preferred dose during pregnancy for treatment experienced patients.